SCHEMBL4049264

SCHEMBL4049264

N#Cc1cc(-c2ccncn2)c(-c2ccco2)[nH]c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 14/20 0.51
ADORA1 P30542 10/20 0.51
ADORA2A P29274 9/20 0.51
ADORA3 P0DMS8 2/20 0.51
ALDH1A1 P00352 3/20 0.44
PDE3B Q13370 3/20 0.42
PDE3A Q14432 3/20 0.42
HPGD P15428 3/20 0.42
KDM4E B2RXH2 2/20 0.42
PDE5A O76074 1/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
PTGS1 P23219 1/20 0.42
PDE4A P27815 1/20 0.42
CYP2C19 P33261 1/20 0.42
BLM P54132 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3835079 0.84 KDM4E (0.57) ALDH1A1PDE3BPDE3AHPGDKDM4E
SCHEMBL4059417 0.81 ALDH1A1 (0.41) ADORA2BADORA1ADORA2AADORA3ALDH1A1
SCHEMBL4051218 0.80 ADORA2B (0.51) ADORA2BADORA1ADORA2AADORA3ALDH1A1
SCHEMBL4052491 0.79 ADORA2B (0.50) ADORA2BADORA1ADORA2AADORA3
SCHEMBL4050353 0.77 PDE3B (0.44) ALDH1A1PDE3BPDE3AHPGDKDM4E
SCHEMBL10984156 0.76 PDE3A (0.67) ADORA2BADORA1ADORA2AADORA3ALDH1A1
SCHEMBL4051186 0.74 ADORA2B (0.59) ADORA2BADORA1ADORA2AADORA3
SCHEMBL4055130 0.74 ADORA2B (0.58) ADORA2BADORA1ADORA2AADORA3ALDH1A1
SCHEMBL10810736 0.69 PDE3B (0.60) ADORA2BADORA1ADORA2AADORA3ALDH1A1
SCHEMBL30463614 0.69 MAPK1 (0.53) ADORA2BADORA1ADORA2AADORA3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
EP-1735310-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma, S.A. (ES) 2006-12-27 EP disclosed
WO-2005100353-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA, SA (ES) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA1 ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.